Table 2.

Pharmacological activity of pascolizumab in vitro^*

Antibody	T-cell proliferation IC50, pm	TF-1 cell proliferation IC25, pm	IgE production IC50, pm	CD23 expression IC50, pm	Tonsil B-cell proliferation IC50, pm
Pascolizumab	157	694	278	950	377
	(113–262)5	(334–1000)3	(240–311)2	(600–1300)2	3/4
MoAb 3B9	31	87	612	147	134
	(11–60)10	(27–139)3	(370–1070)6	(53–272)3	(80–231)4

IC₅₀ = 50% inhibitory concentration; IC₂₅ = 25% inhibitory concentration.

^*Mean (range)_n.